Michael Hughes
Assistant Professor of Medicine
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Michael Hughes is an Assistant Professor of Medicine at Emory University in the United States. His research focuses on diabetes technology, including automated insulin delivery systems and user experiences in hospital settings. Recent articles reflect his commitment to improving diabetes management through innovative technology and the integration of psychosocial factors into patient care.
Articles (10)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Background: Continuous subcutaneous insulin infusion (CSII) is a common treatment option for people with diabetes (PWD), but insulin infusion failures pose a significant challenge, leading to hyperglycemia, diabetes burnout, and increased hospitalizations. Current CSII pumps’ occlusion alarm systems are limited in detecting infusion failures; therefore, a more effective detection method is needed. Methods: We conducted five preclinical animal studies to collect data on infusion failures, utilizing both insulin and non-insulin boluses. Data were captured using in-line pressure and flow rate sensors, with additional force data from CSII pumps’ onboard sensors in one study. A novel classifier model was developed using this dataset, aimed at detecting different types of infusion failures through direct utilization of force sensor data. Performance was compared against various occlusion alarm thresholds from commercially available CSII pumps. Results: The testing dataset included 251 boluses. The Bagging classifier model showed the highest performance metrics among the models tested, exhibiting high accuracy (96%), sensitivity (94%), and specificity (98%), with lower false-positive and false-negative rate compared with traditional occlusion alarm pressure thresholds. Conclusions: Our study developed a novel non-threshold classifier that outperforms current occlusion alarm systems in CSII pumps in detecting infusion failures. This advancement has the potential to reduce the risk of hyperglycemia and hospitalizations due to undetected infusion failures, offering a more reliable and effective CSII therapy for PWD. Further studies involving human participants are recommended to validate these findings and assess the classifier’s performance in a real-world setting.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (4)
Luis Ernesto Blanco
Chief Technology Officer
-
Rayhan A. Lal
Stanford University
Charlotte Boughton
Clinical Lecturer
University of Cambridge
John Wilcox
Co-Founder & Chief Executive Officer
-
Make your next move.
Prepare your application
Review drafts before you send them.